Targeting Janus kinases in the treatment of autoimmune disease

Key Takeaways for GI Nurses

• Janus kinase (JAK) inhibitors are an increasingly important oral therapy option for inflammatory bowel disease (IBD), including ulcerative colitis, and GI nurses will encounter more patients on this drug class in both infusion/injection clinics and general GI practice settings.
• Understanding that JAK3 signaling drives multiple cytokine pathways (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21) helps explain why JAK inhibitors can affect multiple organ systems—nurses should be alert to broad immunosuppressive effects, not just GI-specific ones, when educating patients and monitoring for adverse events.
• Patients on JAK inhibitors require specific pre-treatment screening (TB, hepatitis, lipid panel) and ongoing monitoring (CBC, liver function, lipids, signs of infection or thromboembolism)—GI nurses coordinating care or triaging patient calls should be familiar with these safety parameters.
• This research underscores the value of interdisciplinary awareness—GI nurses benefit from understanding basic immunology/cytokine biology to better communicate with rheumatology and dermatology colleagues managing shared patients with overlapping autoimmune conditions (e.g., psoriatic arthritis with IBD).

Clinical Relevance

This foundational research on JAK3 and cytokine signaling has translated directly into clinically available therapies now used in GI practice. JAK inhibitors (such as tofacitinib and upadacitinib) are approved for ulcerative colitis and are being studied in Crohn's disease, giving GI nurses a growing patient population managed with these oral small-molecule agents rather than traditional biologic infusions or injections. Unlike biologics, JAK inhibitors are pills taken daily, which changes the patient education focus—nurses must counsel on medication adherence, drug interactions, and recognizing early signs of infection, herpes zoster reactivation, or thromboembolic events (DVT/PE), all of which carry boxed warnings for this drug class.

For endoscopy and infusion unit nurses, this means updated intake questionnaires and pre-procedure screening protocols may need to account for JAK inhibitor use, particularly regarding infection risk before colonoscopy or biopsy procedures in immunosuppressed patients. Nurses working in GI clinics should also be prepared to discuss with patients why an oral JAK inhibitor might be selected over a biologic—often due to rapid onset of action, patient preference for avoiding injections, or failure of prior biologic therapy—supporting shared decision-making conversations.

From a professional development standpoint, this research highlights the importance of GI nurses maintaining current knowledge of immunomodulatory pharmacology as treatment paradigms shift from steroid-based and biologic therapies toward targeted small-molecule agents. Nurses who understand the underlying cytokine biology (why blocking JAK3 affects IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 signaling) are better equipped to explain treatment rationale to patients, anticipate potential side effects across multiple organ systems, and collaborate effectively with prescribers on monitoring schedules and dose adjustments.

Bottom Line

JAK inhibitors, born from foundational cytokine signaling research like this, are now a mainstay oral therapy for ulcerative colitis and an emerging option in Crohn's disease—GI nurses should be well-versed in their unique safety monitoring requirements (infection, VTE, lipid, and hepatic surveillance) and patient education needs, as this drug class will continue to expand across the IBD treatment landscape.